Credit: Shutterstock photoMotif Bio, which is developing novel antibiotics effective against multi-drug resistant bacteria, filed on Wednesday with the SEC to raise up to $40 million in an initial public offering. The company is currently listed under the symbol MTFB on LSE's AIM Market and has a market cap of £52 million.
The New York, NY-based company was founded in 2003 and plans to list on the Nasdaq under the symbol MTFB. SunTrust Robinson Humphrey is the sole bookrunner on the deal. No pricing terms were disclosed.
The article Motif Bio files for a $40 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
